TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

Inclusion Criteria

• Age 18 years or older, is willing and able to provide informed consent
• Histologically confirmed diagnosis of unresectable or metastatic solid tumor malignancy in selected tumor types
• Life expectancy > 12 weeks
• ECOG performance status of 0-1 Abbreviated

Exclusion Criteria

• History of allergy or hypersensitivity to study treatment components. Patients with a history of severe hypersensitivity reaction to any monoclonal antibody.
• Use of investigational agent within 28 days prior to the first dose of study treatment and throughout the study
• Receiving high-dose systemic steroid therapy or any other form of immunosuppressive therapy
• History of severe autoimmune disease
• Uncontrolled intercurrent illness or other active malignancy requiring ongoing treatment